Therapeutic radiopharmaceuticals, Chem Rev, vol.99, pp.2269-92, 1999. ,
Radionuclide therapy, Lancet, vol.354, pp.931-936, 1999. ,
URL : https://hal.archives-ouvertes.fr/inserm-01804899
Recent advances in radionuclide therapy, Semin Nucl Med, vol.31, pp.330-371, 2001. ,
Targeted therapy in nuclear medicine-current status and future prospects, Ann Oncol, vol.18, pp.1782-92, 2007. ,
The potential and hurdles of targeted alpha therapy -clinical trials and beyond, Front Oncol, vol.3, p.324, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02168053
Therapeutic radiometals beyond 177 Lu and 90 Y: production and application of promising ?-Particle, ?-Particle, and auger electron emitters, J Nucl Med, vol.58, 2017. ,
Targeted alpha and beta radiotherapy: an overview of radiopharmaceutical and clinical aspects, Med Nucl, vol.42, pp.32-44, 2018. ,
Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations, Target Oncol, vol.13, pp.189-203, 2018. ,
Recent advances in 99m Tc radiopharmaceuticals, Ann Nucl Med, vol.16, pp.79-93, 2002. ,
, , vol.345, 2007.
Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era, Chem Rev, vol.110, pp.2903-2923, 2010. ,
, Coord Chem Rev, vol.172, pp.357-88, 1996.
Basic aqueous chemistry of [M(OH 2 ) 3 (CO) 3 ] + . (M = Re, Tc) directed towards radiopharmaceutical application, Coord Chem Rev, pp.190-192, 1999. ,
Rhenium(V) Complexes: from pure hard donors to mixed soft/hard functionalized phosphine ligands, Rev Inorg Chem, vol.19, pp.187-210, 1999. ,
Labeling biomolecules with radiorhenium -a review of the bifunctional chelators, Anticancer Agents Med Chem, vol.7, pp.367-77, 2007. ,
Re(VII) and Tc(VII) trioxo complexes stabilized by tridentate ligands and their potential use as radiopharmaceuticals, Coord Chem Rev, vol.276, pp.97-111, 2014. ,
Measurements of 186 Re production cross section induced by deuterons on nat W target at ARRONAX facility, Nucl Med Biol, vol.41, pp.16-24, 2014. ,
Preparation of cyclotron-produced 186 Re and comparison with reactorproduced 186 Re and generator-produced 188 Re for the labeling of bombesin, Nucl Med Biol, vol.33, pp.81-90, 2006. ,
The biomedical chemistry of technetium and rhenium, Chem Soc Rev, vol.27, pp.43-55, 1998. ,
, Chelated hydrazido(3-)rhenium(V) complexes: on the way to the nitrido-M(V) core (M = Tc, Re), vol.41, pp.1591-1598, 2002.
Design, synthesis, and reactivity of multidentate ligands with Rhenium(I) and Rhenium(V) Cores, Eur J Inorg Chem, pp.3908-3926, 2017. ,
The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine, Nucl Med Biol, vol.13, issue.86, pp.90027-90036, 1986. ,
Role of 99m Tc in the development of rhenium radiopharmaceuticals, Technetium-99m Radiopharmaeuticals: Status and Trends. Vienna: IAEA Radioisotopes and Radiopharmaceuticals Series, p.1, 2010. ,
Ligand exchange and complex formation kinetics studied by NMR exemplified on fac, Coord Chem Rev, vol.252, pp.2346-61, 2008. ,
The role of coordination chemistry in the development of copper and rhenium radiopharmaceuticals, Dalton Trans, vol.40, pp.999-1010, 2011. ,
Rhenium-188 radiochemistry: challenges and prospects, Int J Nucl Med Res, pp.39-53, 2017. ,
Rhenium-188 -a generator-derived radioisotope for cancer therapy cancer, Cancer Biother Radiopharm, vol.13, pp.337-386, 1998. ,
Rhenium-188: availability from the 188 W/ 188 Re generator and status of current applications, Curr Radiopharm, vol.5, pp.228-231, 2012. ,
Rhenium-188 generatorbased radiopharmaceuticals for therapy, Medical Radiology, 2012. ,
Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy, Int J Mol Imaging, vol.3, p.290750, 2013. ,
An overview of radioisotope separation technologies for development of 188 W/ 188 Re radionuclide generators providing 188 Re to meet future research and clinical demands, vol.5, pp.39012-39048, 2015. ,
Continued availability of the tungsten-188/rhenium-188 generator to enhance therapeutic utility of 188 Re Int, J Nucl Med Res, pp.3-15, 2017. ,
Rhenium-188 as a therapeutic radionuclide in lowincome and middle-income countries, Nucl Med Commun, vol.39, pp.1-2, 2018. ,
Reactor production and processing of therapeutic radioisotopes for applications in nuclear medicine, J Radioanal Nucl Chem, vol.205, pp.93-100, 1996. ,
Production of therapeutic radioisotopes in the ORNL High Flux Isotope Reactor. (HFIR) for applications in nuclear medicine, oncology and interventional cardiology, J Radioanal Nucl Chem, vol.263, pp.503-512, 2005. ,
Reactor Production and Processing of 188 W. In: Production of Long Lived Parent Radionuclides for Generators: 68 Ge, 82 Sr, 90 Sr and 188 W, International Atomic Energy Agency. Vienna: (IAEA) Radioisotopes and Radiopharmaceutical Series, issue.2, 2010. ,
Burn-up Cross Section of 188 W, Radiochim Acta, vol.77, pp.99-102, 1997. ,
Issues associated with the use of the Tungsten-188/Rhenium188 generator and concentrator system and preparation of Re-188 HDD: A report, World J Nucl Med, vol.3, pp.137-143, 2004. ,
Russ) Jr. Thermoseparation of neutron-irradiated tungsten from Re and Os, Indust Engineer Chem Res, vol.39, pp.3169-72, 2000. ,
The tungsten-188/rhenium-188 generator: effective coordination of tungsten-188 production between the HFIR and BR2 Reactors, J Radioanal Nucl Chem, vol.257, pp.169-174, 2003. ,
Production of 70-day W-188 and development of a 17-hour Re-188 radioisotope generator, J Nucl Med, vol.7, pp.804-809, 1966. ,
Processing of reactor-produced tungsten-188 for fabrication of clinical scale alumina-based tungsten-188/Rhenium-188 generators, Appl Radiat Isot, vol.45, pp.1123-1131, 1994. ,
Recovery of enriched 186 W from spent 188 W/ 188 Re generators, Appl Radiat Isot, vol.47, pp.727-736, 1996. ,
Tungsten-188/Rhenium-188 generator for biomedical applications, Radiochim Acta, vol.65, pp.39-46, 1994. ,
Development of a high performance 188 W/ 188 Re generator using synthetic alumina, Appl Radiat Isot, vol.67, pp.1162-1168, 2009. ,
Development of semiautomated system for preparation of 188 Re aqueous solutions of high and reproducible activity concentrations, Appl Radiat Isot, vol.63, pp.299-304, 2005. ,
A design for automatic preparation of highly concentrated 188 Re-perrhenate solutions, Appl Radiat Isot, vol.65, pp.21-26, 2007. ,
A semi-automated system for concentration of rhenium-188 for radiopharmaceutical applications, Appl Radiat Isot, vol.66, pp.1876-80, 2008. ,
Studies on the preparation and isomeric composition of [ 186 Re]-and [ 188 Re]-pentavalent rhenium dimercaptosuccinic acid complex, Nucl Med Commun, vol.14, pp.197-203, 1993. ,
High specific volume rhenium-188 -clinical potential of a readily available therapeutic radioisotope Nuklearmedizin, vol.36, p.38, 1997. ,
Extending the life of a 99m Tc generator: a simple and convenient method for concentrating generator eluate for clinical use, Nucl Med Commun, vol.14, pp.995-1002, 1993. ,
Simple new method for effective concentration of 188 Re solutions from alumina-based 188 W-188 Re Generator, J Nucl Med, vol.41, pp.1271-1278, 2000. ,
, Nucl Med Commun, vol.25, pp.957-62, 2004.
Evaluation of two methods for concentrating perrhenate. ( 188 Re) eluates obtained from 188 W-188 Re generator, Appl Radiat Isot, vol.67, pp.234-243, 2009. ,
Post-elution concentration of 188 Re by an electrochemical method, Appl Radiat Isot, vol.68, pp.2302-2307, 2010. ,
Development of multiple-elution cartridgebased radioisotope concentrator device for increasing the 99m Tc and 188 Re concentration and the effectiveness of 99m Tc/ 99 Mo utilisation, J Radioanal Nucl Chem, vol.303, pp.1173-1181, 2015. ,
Concentration protocol of rhenium-188 perrhenate eluted from tungsten-188/rhenium-188 generator for the preparation of high-yield rhenium-188-labelled radiopharmaceuticals, Nucl Med Commun, vol.39, pp.957-966, 2018. ,
The Na/I symporter. (NIS): imaging and therapeutic applications, Semin Nucl Med, vol.34, pp.23-31, 2004. ,
A perspective view of sodium iodide symporter research and its clinical implications, Eur J Endocrinol, vol.155, pp.495-512, 2006. ,
Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo, J Nucl Med, vol.45, pp.500-507, 2004. ,
Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter. (NIS), Nucl Med Biol, vol.29, pp.13-21, 2002. ,
Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth, Nucl Med Biol, vol.32, pp.695-700, 2005. ,
Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression, J Clin Endocrinol Metab, vol.92, pp.4451-4459, 2007. ,
Sodium iodide symporter. (NIS)-mediated radionuclide. ( 131 I, 188 Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery, Hum Gene Ther, vol.22, pp.1403-1415, 2011. ,
Use of rhenium-188 for in vivo imaging and treatment of human cervical cancer cells transfected with lentivirus expressing sodium iodide symporter, Oncol Rep, vol.36, pp.2289-97, 2016. ,
Radiovirotherapy: principles and prospects in oncology, Curr Pharm Des, vol.18, pp.3313-3333, 2012. ,
Rhenium and technetium based radiopharmaceuticals: Development and recent advances, J Organomet Chem, vol.751, pp.83-92, 2014. ,
Guidelines for 99m Tc-DMSA scintigraphy in children, Eur J Nucl Med, vol.28, pp.37-41, 2001. ,
MDP-an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid, J Nucl Med, vol.29, pp.33-41, 1988. ,
An alternative approach to the preparation of 188Re radiopharmaceuticals from generator-produced, Nucl Med Biol, vol.27, pp.309-323, 2000. ,
Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies, Eur J Nucl Med, vol.25, pp.613-634, 1998. ,
Uptake of the 188 Re(V)-DMSA complex by cervical carcinoma cells in nude mice: pharmacokinetics and dosimetry, Appl Radiat Isot, vol.54, pp.413-421, 2001. ,
V)DMSA quantitatively predicts 188 Re(V)DMSA distribution in patients with prostate cancer metastatic to bone, Eur J Nucl Med, vol.27, pp.1405-1414, 2000. ,
188 Re(V)-DMSA revisited: preparation and biodistribution of a potential radiotherapeutic agent with low kidney uptake, Nucl Med Commun, vol.19, pp.173-81, 1998. ,
Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials, J Exp Clin Cancer Res, vol.36, p.108, 2017. ,
Recent developments in nuclear medicine in the management of bone metastases: a review and perspective, Am J Clin Oncol, vol.28, pp.513-533, 2005. ,
Internal radiotherapy of painful bone metastases, Methods, vol.55, 2011. ,
Radiometabolic treatment of bone-metastasizing cancer: from 186 rhenium to 223 radium, Cancer Biother Radiopharm, vol.29, pp.1-11, 2014. ,
Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis, Am J Nucl Med Mol Imaging, vol.3, pp.437-482, 2013. ,
Systemic Radioligand Therapy with 177 Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer, J Urol, vol.196, pp.382-91, 2016. ,
Studies on neoplasms with the aid of radioactive phosphorus. I. The total phosphorus metabolism of normal and leukemic mice, J Clin Invest, vol.19, pp.267-71, 1940. ,
Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms ,
, Int J Appl Radiat Isot, vol.30, pp.725-732, 1979.
Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background, Semin Nucl Med, vol.22, pp.11-17, 1992. ,
Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions, J Nucl Med, vol.41, pp.682-689, 2000. ,
Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice, Q J Nucl Med, vol.45, pp.18-26, 2001. ,
From palliative therapy to prolongation of survival: 223 RaCl 2 in the treatment of bone metastases, Ther Adv Med Oncol, vol.8, pp.294-304, 2016. ,
Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons, Clin Exp Metastasis, vol.34, pp.1-10, 2017. ,
Bone-targeting radiopharmaceuticals as monotherapy or combined with chemotherapy in patients with castrationresistant prostate cancer metastatic to bone, Clin Genitourin Cancer, vol.17, pp.281-92, 2018. ,
Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153, Appl Radiat Isot, vol.110, pp.87-99, 2016. ,
Rhenium-188(Sn)HEDP for treatment of osseous metastases, J Nucl Med, vol.39, pp.659-63, 1998. ,
Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases, Eur J Nucl Med, vol.27, pp.123-153, 2000. ,
Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose, BMC Nucl Med, vol.1, 2001. ,
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate, J Clin Oncol, vol.21, pp.2869-75, 2003. ,
Palliation and survival after repeated 188 Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis, J Nucl Med, vol.52, pp.1721-1727, 2011. ,
Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy, Clin Nucl Med, vol.25, pp.901-905, 2000. ,
Comparison of Rhenium-188, Rhenium-186-HEDP and Strontium-89 in palliation of painful bone metastases, Nuklearmedizin, vol.39, pp.146-51, 2000. ,
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain, J Cancer Res Clin Oncol, vol.131, pp.60-66, 2005. ,
A comparative study of 188 Re-HEDP, 186 Re-HEDP, 153 Sm-EDTMP and 89 Sr in the treatment of painful skeletal metastases ,
, Nucl Med Commun, vol.28, pp.623-653, 2007.
Dosimetry of 188 Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases, J Nucl Med, vol.44, pp.953-60, 2003. ,
Rhenium-188-HEDP in the palliative treatment of bone metastases, Cancer Biother Radiopharm, vol.15, pp.261-266, 2000. ,
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases, Br J Cancer, vol.89, pp.625-634, 2003. ,
Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients, Cancer Biother Radiopharm, vol.18, pp.719-745, 2003. ,
Rhenium-188 HEDP to treat painful bone metastases, Clin Nucl Med, vol.26, pp.919-941, 2001. ,
The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases, Cancer Biother Radiopharm, vol.26, pp.237-281, 2011. ,
Clinical utility of 188 Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies, World J Nucl Med, vol.17, pp.228-263, 2018. ,
Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study, Nuklearmedizin, vol.55, pp.188-95, 2016. ,
May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on 188 Re-HEDP treatment in progressive bone metastases after 177 Lu-octreotate, Am J Nucl Med Mol Imaging, vol.4, pp.80-88, 2014. ,
188 Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study, Eur J Nucl Med Mol Imaging, vol.369, pp.1425-1458, 2009. ,
Cytotoxic effects of the therapeutic radionuclide rhenium-188 combined with taxanes in human prostate carcinoma cell lines, Cancer Biother Radiopharm, vol.32, pp.16-23, 2017. ,
Rhenium-188-HEDP-kit formulation and quality control, Radiochim Acta, vol.2, pp.113-120, 1997. ,
Synthesis of a 188 Re-HEDP complex using carrier-free 188 Re, and a study of its stability, Appl Radiat Isot, vol.49, pp.351-357, 1998. ,
Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases, Nucl Med Biol, vol.26, pp.973-979, 1999. ,
Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes, Nucl Med Biol, vol.26, pp.455-464, 1999. ,
Influence of reactant concentrations and solution acidity on the complexation of 188 Re with 1-hydroxyethane-1,1-diphosphonic acid, Radiochemistry, vol.50, pp.203-210, 2008. ,
Synthesis of a 188 Re-HEDP complex using carrier-free 188 Re and a study of its stability and biological distribution, Radiochemistry, vol.53, pp.352-358, 2011. ,
Evaluation of the influence of preparation conditions on pharmacokinetics of bone-seeking radiopharmaceutical 188Re-labeled hydroxyethylidenediphosphonic acid monopotassium salt in rats, Pharm Chem J, vol.46, pp.443-451, 2012. ,
Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188 Rhenium-HEDP, Nucl Med Biol, vol.42, pp.465-474, 2015. ,
Applying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical ,
Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases, Eur J Pharm Sci, vol.30, pp.317-341, 2014. ,
188 Re zoledronic acid in the palliative treatment of painful bone metastases, Int J Nucl Med Res, pp.92-100, 2017. ,
Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases, Bone, vol.91, pp.159-79, 2016. ,
Current status and perspectives in peptide receptor radiation therapy, Curr Pharm Des, vol.15, pp.2453-62, 2009. ,
Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers, Front Oncol, vol.3, p.247, 2013. ,
Russ) Jr. Peptide receptor radionuclide therapy: an overview, Cancer Biother Radiopharm, vol.30, pp.47-71, 2015. ,
Radioimmunotherapy of human tumours, Nat Rev Cancer, vol.15, pp.347-60, 2015. ,
Radioimmunotherapy: from current clinical success to future industrial breakthrough?, J Nucl Med, vol.57, pp.329-360, 2016. ,
Advances in cancer therapy with radiolabeled monoclonal antibodies, Q J Nucl Med Mol Imaging, vol.50, pp.248-64, 2006. ,
Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy, Biomed Res Int, p.5923609, 2017. ,
188 Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia, Leukemia Lymphoma, vol.43, pp.2125-2156, 2002. ,
De Vos F. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of Bcell chronic lymphocytic leukemia, Nucl Med Biol, vol.35, pp.599-604, 2008. ,
Biokinetics and dosimetry of 188 Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience, Arch Med Res, vol.39, pp.100-109, 2008. ,
The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188 Re-herceptin, Nucl Med Biol, vol.32, pp.59-65, 2005. ,
Evaluating the potential of 188 Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment, Nucl Med Biol, vol.36, pp.81-89, 2009. ,
Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma, Int J Radiat Biol, vol.89, pp.346-55, 2013. ,
Re-188 enhances the inhibitory effect of bevacizumab in non-small-cell lung cancer, Molecules, vol.21, p.1308, 2016. ,
Characteristics and NanoSPECT/CT Imaging of 188 Recetuximab in NCI-H292 Human Lung Cancer Xenografts, Anticancer Res, vol.39, pp.183-90, 2019. ,
High dose of hR-3, an anti-epidermal growth factor receptor monoclonal antibody labeled with 188 rhenium following intravenous injection into rats, J Appl Res, vol.6, pp.77-88, 2006. ,
Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anticarcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer, J Nucl Med, vol.39, pp.34-42, 1998. ,
Production and characterization of 188 Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer, J Nucl Med, vol.42, pp.726-758, 2001. ,
Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R), Nucl Med Biol, vol.43, pp.812-819, 2016. ,
Radioimmunotherapy and apoptotic induction on Ck19-overexpressing human cervical carcinoma cells with Re ,
, Anticancer Res, vol.25, pp.2719-2747, 2005.
Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer, Cancer Med, vol.5, pp.9-16, 2016. ,
Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer, Proc Natl Acad Sci, vol.110, pp.8668-73, 2013. ,
Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy, Sci Rep, vol.8, p.5466, 2018. ,
Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia, Eur J Nucl Med, vol.26, pp.1265-73, 1999. ,
Rhenium 188-labeled anti-CD66. (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study, Blood, vol.98, pp.565-72, 2001. ,
Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities, Cancer Biother Radiopharm, vol.17, pp.151-63, 2002. ,
188 Re or 90 Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study ,
, Br J Haematol, vol.130, pp.604-617, 2005.
188 Re anti-CD66 radioimmunotherapy combined with reducedintensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation, Br J Haematol, vol.148, pp.910-917, 2010. ,
Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibodies, Blood, vol.99, pp.2270-2271, 2002. ,
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation, J Nucl Med, vol.47, pp.278-86, 2006. ,
Reduced-intensity conditioning combined with 188 Rhenium radioimmunotherapy before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: the role of in vivo t cell depletion, Biol Blood Marrow Transplant, vol.21, pp.1754-60, 2015. ,
188 Relabelled McAb 3H11 used as preventive for the peritoneal micro-metastasis of gastric cancer, Nuclear Science and Techniques, vol.10, pp.203-209, 1999. ,
Biodistribution and internal dosimetry of the 188 Re-labelled humanized monoclonal antibody anti-epidermal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas, Nucl Med Commun, vol.29, pp.66-75, 2008. ,
Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma, Cancer Biol Ther, vol.7, pp.333-342, 2008. ,
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma, J Skin Cancer, p.828329, 2013. ,
Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin, Proc Natl Acad Sci, vol.101, 2004. ,
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection, Proc Natl Acad Sci, vol.100, pp.10942-10949, 2003. ,
Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax, Antimicrob Agents Chemother, vol.53, pp.4860-4868, 2009. ,
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins, PLoS Med, vol.3, p.427, 2006. ,
Chelating systems for 99m Tc/ 188 Re in the development of radiolabeled peptide pharmaceuticals, Anticancer Agents Med Chem, vol.12, pp.428-61, 2012. ,
Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma, Bioconjug Chem, vol.18, pp.1739-1787, 2007. ,
Synthesis, characterization, and in vitro evaluation of new 99m Tc/Re(V)-cyclized octreotide analogues: an experimental and computational approach, Inorg Chem, vol.55, pp.1124-1157, 2016. ,
Preparation of 188 Re-RC-160 somatostatin analog: a peptide for local/regional radiotherapy, Appl Radiat Isot, vol.48, pp.226-232, 1997. ,
Uptake of 188 Re-beta-naphthylpeptide in cervical carcinoma tumours in athymic mice, Nucl Med Biol, vol.28, pp.319-345, 2001. ,
Radiopharmacokinetic and dosimetric parameters of 188 Relanreotide in athymic mice with induced human cancer tumors, Int J Pharm, vol.310, pp.125-155, 2006. ,
Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies, J Med Chem, vol.50, pp.1354-64, 2007. ,
Therapeutic effect of 188 Re-MAG 3 -depreotide on non-small cell lung cancer in vivo and in vitro, Int J Clin Exp Pathol, vol.6, pp.421-451, 2013. ,
Evaluation of 188 Re-MAG2-RGD-bombesin for potential prostate cancer therapy, Nucl Med Biol, vol.40, pp.182-191, 2013. ,
Effective way to radiolabel the peptide of MAG 3 -RM26 with 188 Re and the study on its coordination chemistry, J Radioanal Nucl Chem, vol.314, pp.2087-90, 2017. ,
Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with Substance-P, Appl Radiat Isot, vol.92, pp.25-31, 2014. ,
Investigation of SP94 Peptide as a specific probe for hepatocellular carcinoma imaging and therapy, vol.6, p.33511, 2016. ,
Novel small peptides derived from VEGF 125?136 : potential drugs for radioactive diagnosis and therapy in A549 tumor-bearing nude mice, vol.7, p.4278, 2017. ,
Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy, Biomaterials, vol.94, pp.31-44, 2016. ,
Peptide-targeted radionuclide therapy for melanoma, Crit Rev Oncol Hematol, vol.67, pp.213-241, 2008. ,
-labeled ?-melanocyte stimulating hormone peptide analogs: effects of cyclization on the radiopharmaceutical properties, Nucl Med Biol, vol.43, pp.788-801, 2016. ,
Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog, J Thorac Oncol, vol.4, pp.1550-1554, 2009. ,
Yttrium-90 microspheres: a review of its emerging clinical indications, Liver Cancer, vol.4, pp.6-15, 2015. ,
Intra-arterial radionuclide therapies for liver tumors, Semin Nucl Med, vol.46, pp.324-363, 2016. ,
, Transarterial radioembolisation (TARE) agents beyond 90 Y-microspheres
, Biomed Res Int, p.1435302, 2018.
Transarterial radionuclide therapy with 188 Re-labelled lipiodol, Int J Nucl Med Res, pp.79-91, 2017. ,
Lipiodol solution of 188 Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model, J Nucl Med, vol.44, pp.2033-2041, 2003. ,
A kit formulation for the preparation of 188 Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma, Nucl Med Commun, vol.25, pp.691-700, 2004. ,
188 Re-SSS/Lipiodol: development of a potential treatment for HCC from bench to bedside, Int J Mol Imaging, p.278306, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00866975
Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radioconjugates, Ann Acad Med, vol.31, pp.382-388, 2002. ,
Preliminary results of transarterial rhenium-188 HDD Lipiodol in the treatment of inoperable primary hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, vol.31, pp.250-257, 2004. ,
Biologic dosimetry of 188 Re-HDD/Lipiodol versus 131 I-Lipiodol therapy in patients with hepatocellular carcinoma, J Nucl Med, vol.45, pp.612-620, 2004. ,
188 Re-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial, J Nucl Med, vol.46, pp.60-66, 2005. ,
188 Re-HDD/Lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis, J Nucl Med, vol.46, pp.1326-1358, 2005. ,
Radiolabeled Lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome, Cancer Biother Radiopharm, vol.20, pp.209-223, 2005. ,
Transarterial radionuclide therapy with Re-188-HDD-lipiodol in case of unresectable hepatocellular carcinoma with extensive portal vein thrombosis, Eur J Radiology Extra, vol.56, pp.55-64, 2005. ,
Management of postsurgical recurrence of hepatocellular carcinoma with Rhenium 188-HDD labeled iodized oil ,
, J Vasc Interv Radiol, vol.17, pp.157-161, 2006.
Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-Lipiodol, Eur J Gastroenterol Hepatol, vol.18, pp.219-222, 2006. ,
188 Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study, Eur J Nucl Med Mol Imaging, vol.33, pp.344-52, 2006. ,
Inoperable hepatocellular carcinoma: transarterial 188 Re HDD-labeled iodized oil for treatment prospective multicenter clinical trial, Radiology, vol.243, pp.509-528, 2007. ,
Intra-arterial Rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study, Int J Radiat Oncol Biol Phys, vol.69, pp.1448-55, 2007. ,
International Atomic Energy Agency sponsored multination study of intra-arterial rhenium-188-labeled Lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study, Sem Nucl Med, vol.38, pp.40-45, 2008. ,
Biodistribution, pharmacokinetics, and organ-level dosimetry for 188 Re-AHDDLipiodol radioembolization based on quantitative post-treatment SPECT/CT scans, EJNMMI Physics, vol.5, p.30, 2018. ,
Biodistribution and dosimetry assessments for hepatocellular carcinoma treated with 188 Re-SSS Lipiodol: Preliminary results of the phase 1 trial Lip Re 1, J Nucl Med, vol.59, p.602, 2018. ,
Management of liver cancer using radionuclide methods with special emphasis on trans-arterial radio-conjugate therapy and internal dosimetry, Semin Nucl Med, vol.38, pp.5-12, 2008. ,
Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol. (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol, Nucl Med Biol, vol.42, pp.317-322, 2015. ,
Preparation and properties of radioactive rhenium glass microspheres intended for in vivo radioembolization therapy, J Biomed Mater Res, vol.42, pp.617-642, 1998. ,
Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma, J Nucl Med, vol.39, pp.1752-1759, 1998. ,
Labeling and biodistribution of different particle materials for radioembolization therapy with 188 Re, Appl Radiat Isot, vol.62, pp.745-50, 2005. ,
68 Ga and 188 Re starch-based microparticles as theranostic tool for the hepatocellular carcinoma: radiolabeling and preliminary in vivo rat studies, PLoS ONE, vol.11, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01398433
Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization, Jpn J Clin Oncol, vol.37, pp.942-50, 2007. ,
Initial study of radiological and clinical efficacy radioembolization using 188 Re-human serum albumin. (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers, Med Sci Monit, vol.20, pp.1353-62, 2014. ,
Advantage of 188 Re-radiopharmaceuticals in hepatocellular cancer and liver metastases, J Nucl Med, vol.46, pp.1407-1415, 2005. ,
Radionuclide therapy revisited, Eur J Nucl Med, vol.18, pp.408-439, 1991. ,
Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals, Nucl Med Biol, vol.28, pp.835-879, 2001. ,
Fibrin glue system for adjuvant brachytherapy of brain tumors with 188 Re and 186 Relabeled microspheres, Eur J Pharm Biopharm, vol.65, pp.282-290, 2007. ,
Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with 188 Re-lipid nanocapsules, Biomaterials, vol.32, pp.6781-90, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00638699
Characterization of the distribution, retention, and efficacy of internal radiation of 188 Re-lipid nanocapsules in an immunocompromised human glioblastoma model, J Neurooncol, vol.131, pp.49-58, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01451658
Locoregional confinement and major clinical benefit of 188 Re-Loaded CXCR4-targeted nanocarriers in an orthotopic human to mouse model of glioblastoma, Theranostics, vol.7, pp.4517-4553, 2017. ,
Radiobiological characterization of post-lumpectomy focal brachytherapy with lipid nanoparticle-carried radionuclides, Phys Med Biol, vol.56, pp.703-722, 2011. ,
Postlumpectomy focal brachytherapy for simultaneous treatment of surgical cavity and draining lymph nodes, Int J Radiat Oncol Biol Phys, vol.79, pp.948-55, 2011. ,
Direct intratumoral infusion of liposome encapsulated rhenium radionuclides for cancer therapy: effects of nonuniform intratumoral dose distribution, Med Phys, vol.38, pp.1339-1386, 2011. ,
Improved tumour response prediction with equivalent uniform dose in pre-clinical study using direct intratumoural infusion of liposome-encapsulated 86 Re radionuclides, Phys Med Biol, vol.56, pp.5721-5755, 2011. ,
188 Reliposome can induce mitochondrialautophagy and reverse drug resistance for ovarian cancer: from bench evidence to preliminary clinical proof-ofconcept, Int J Mol Sci, vol.18, p.903, 2017. ,
Radiosynovectomy using yttrium-90, phosphorus-32 or rhenium-188 radiocolloids versus corticoid instillation for rheumatoid arthritis of the knee, Ann Nucl Med, vol.25, pp.317-340, 2011. ,
Preparation of 188 Re-labeled paper for treating skin cancer, Appl Radiat Isot, vol.58, pp.551-556, 2003. ,
Noninvasive treatment of keloid using customized Re-188 skin patch ,
, Dermatol Ther, vol.30, 2017.
188 Re Tailor Made Skin Patch for the treatment of skin cancers and keloid: overview and technical considerations, Int J Nucl Med Res, pp.107-113, 2017. ,
Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma, Clin Exp Dermatol, vol.33, pp.745-754, 2008. ,
Personalized highdose-rate brachytherapy with non-sealed rhenium-188 in non-melanoma skin cancer, Int J Nucl Med Res, pp.114-136, 2017. ,
Dermo beta brachytherapy with 188 Re in squamous cell carcinoma of the penis: a new therapy, Eur J Dermatol, vol.23, pp.183-191, 2013. ,
Dermo Beta Brachytherapy with 188 Re in extramammary Paget's disease, G Ital Dermatol Venereol, vol.149, pp.115-136, 2014. ,